AU2016363114B2 - Regulation of cytokine production - Google Patents

Regulation of cytokine production Download PDF

Info

Publication number
AU2016363114B2
AU2016363114B2 AU2016363114A AU2016363114A AU2016363114B2 AU 2016363114 B2 AU2016363114 B2 AU 2016363114B2 AU 2016363114 A AU2016363114 A AU 2016363114A AU 2016363114 A AU2016363114 A AU 2016363114A AU 2016363114 B2 AU2016363114 B2 AU 2016363114B2
Authority
AU
Australia
Prior art keywords
gly
ser
gln
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016363114A
Other languages
English (en)
Other versions
AU2016363114A1 (en
Inventor
Rebecca AMBROSE
Andrew Bean
Cameron Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905035A external-priority patent/AU2015905035A0/en
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of AU2016363114A1 publication Critical patent/AU2016363114A1/en
Application granted granted Critical
Publication of AU2016363114B2 publication Critical patent/AU2016363114B2/en
Priority to AU2023204701A priority Critical patent/AU2023204701A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
AU2016363114A 2015-12-04 2016-12-02 Regulation of cytokine production Active AU2016363114B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023204701A AU2023204701A1 (en) 2015-12-04 2023-07-14 Regulation of cytokine production

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015905035A AU2015905035A0 (en) 2015-12-04 Regulation of cytokine production
AU2015905035 2015-12-04
PCT/AU2016/051192 WO2017091866A1 (en) 2015-12-04 2016-12-02 Regulation of cytokine production

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023204701A Division AU2023204701A1 (en) 2015-12-04 2023-07-14 Regulation of cytokine production

Publications (2)

Publication Number Publication Date
AU2016363114A1 AU2016363114A1 (en) 2018-07-05
AU2016363114B2 true AU2016363114B2 (en) 2023-04-20

Family

ID=58796001

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016363114A Active AU2016363114B2 (en) 2015-12-04 2016-12-02 Regulation of cytokine production
AU2023204701A Pending AU2023204701A1 (en) 2015-12-04 2023-07-14 Regulation of cytokine production

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023204701A Pending AU2023204701A1 (en) 2015-12-04 2023-07-14 Regulation of cytokine production

Country Status (8)

Country Link
US (1) US20180362625A1 (enExample)
EP (1) EP3383408A4 (enExample)
JP (3) JP2019503998A (enExample)
KR (1) KR20180088455A (enExample)
CN (1) CN108601794A (enExample)
AU (2) AU2016363114B2 (enExample)
CA (1) CA3007287A1 (enExample)
WO (1) WO2017091866A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
CN107964564B (zh) * 2017-12-28 2020-09-11 中南大学湘雅医院 胶质瘤诊断标志物circ6:34606555|34606904及应用
KR102805517B1 (ko) * 2022-12-22 2025-05-12 주식회사 셀렉소바이오 강직성 척추염 진단용 조성물, 키트 및 이의 정보제공방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313313A (zh) * 2000-03-10 2001-09-19 上海博德基因开发有限公司 一种新的多肽——人cdc4类似蛋白12和编码这种多肽的多核苷酸
US20030013651A1 (en) * 2001-03-22 2003-01-16 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
CA2628300C (en) * 2005-11-02 2018-04-17 Protiva Biotherapeutics, Inc. Modified sirna molecules and uses thereof
KR101629963B1 (ko) * 2008-07-21 2016-06-14 경희대학교 산학협력단 염증성 질환 진단용 ｃＤＮＡ 마이크로어레이 칩
CN101773668B (zh) * 2009-01-09 2012-09-12 中国科学院上海生命科学研究院 一种抗病毒相关蛋白及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"PREDICTED: uncharacterized protein C6orf106 homolog isoform X2 [Nomascus leucogenys].", NCBI, (2013-01-14), Database accession no. XP_003278868 .2., URL: NCBI *
JIANG, G. et al., "A novel biomarker C6orf106 promotes the malignant progression of breast cancer.", Tumour Biol., (2015-09), vol. 36, no. 10, pages 7881-9 *
NCBI Reference Sequence: NP_001026090. protein ILRUN [Gallus gallus]. Full-length cDNAs from chicken bursal lymphocytes to facilitate gene function analysis. 2005. Online: https://www.ncbi.nlm.nih.gov/protein/NP_001026090.1 *
ZHANG, X. et al. "C6orf106 enhances NSCLC cell invasion by upregulating vimentin, and downregulating E-cadherin and P120ctn." Tumour Biol. 2015 Aug;36(8):5979-85 *

Also Published As

Publication number Publication date
KR20180088455A (ko) 2018-08-03
CA3007287A1 (en) 2017-06-08
AU2016363114A1 (en) 2018-07-05
EP3383408A4 (en) 2019-06-26
JP2022028689A (ja) 2022-02-16
EP3383408A1 (en) 2018-10-10
US20180362625A1 (en) 2018-12-20
AU2023204701A1 (en) 2023-09-28
WO2017091866A1 (en) 2017-06-08
JP2024041751A (ja) 2024-03-27
JP2019503998A (ja) 2019-02-14
CN108601794A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
AU2022241521B2 (en) Shared neoantigens
US10479997B2 (en) Compositions and methods for diagnosis and treatment of prostate cancer
US20220168419A1 (en) Compositions and methods for treating autoimmune diseases and cancers
AU2015202068B2 (en) Sting (stimulator of interferon genes), a regulator of innate immune responses
AU2023204701A1 (en) Regulation of cytokine production
US20180010132A1 (en) Inhibition of prmt5 to treat mtap-deficiency-related diseases
Shibasaki et al. Peculiar monomeric interferon gammas, IFN γrel 1 and IFN γrel 2, in ginbuna crucian carp
Linder et al. Defective interfering genomes and the full-length viral genome trigger RIG-I after infection with vesicular stomatitis virus in a replication dependent manner
US20250163126A1 (en) Artificial synapses
Li et al. Rabies virus phosphoprotein interacts with ribosomal protein L9 and affects rabies virus replication
Ma et al. The low-density lipoprotein receptor promotes infection of multiple encephalitic alphaviruses
US20190263899A1 (en) Compositions, methods, and therapeutic uses related to fusogenic protein minion
Du et al. IFITM3 inhibits severe fever with thrombocytopenia syndrome virus entry and interacts with viral Gc protein
Zhao et al. Avian influenza viruses suppress innate immunity by inducing trans-transcriptional readthrough via SSU72
US10954515B2 (en) Therapeutic methods, products and compositions inhibiting ZNF555
JP6653120B2 (ja) Ｉｋａｒｏｓ阻害に基づく抗炎症薬
Wei et al. Negative regulation of interferon-β production by alternative splicing of tumor necrosis factor receptor-associated factor 3 in ducks
WO2021009763A1 (en) Methods of treating pain
CN120858177A (zh) Ofd1蛋白或基因作为靶点在肿瘤预防与治疗中的应用
WO2025054363A1 (en) Minigene cassettes, recombinant polynucleotides, and methods of their use
WO2012138575A1 (en) Compositions and methods for increasing muscle function and mass
JP2009207467A (ja) Ｔｏｌｌ様受容体３遺伝子導入マウスから樹立した細胞株並びにＴｏｌｌ様受容体３のアゴニスト又はアンタゴニストのスクリーニング方法。

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)